Article

The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific Manner

2024-04-22

Abstract excerpt

<h4>Background</h4> Sodium/glucose cotransporter 2 inhibitors (SGLT2is) such as empagliflozin have demonstrated substantial cardioprotective effects in patients with or without diabetes. The SGLT2is have been shown to selectively inhibit the late component of cardiac sodium current (late I Na ). Induction of late I Na is also the primary mechanism involved in the pathophysiology of congenital long QT syndrome t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b460b706-b1e7-5fe1-98de-bedbf615a946
DOI: 10.1101/2024.04.15.589662

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin Inhibits Long QT 3 Late Sodium Currents in a Mutation Specific MannerDOI 10.1101/2024.04.15.589662Read

The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner.Semantic proximity Read

The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Na <sub>v</sub> 1.5 channelsSemantic proximity Read

The efficacy of Ranolazine on E1784K is altered by temperature and calcium.Semantic proximity Read

The role of late I Na in development of cardiac arrhythmias.Semantic proximity Read

Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.Semantic proximity Read

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?Semantic proximity Read

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read

The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ NaV1.5 Mutant of the Long QT Type 3 Syndrome.Semantic proximity Read

Late cardiac sodium current can be assessed using automated patch-clampSemantic proximity Read

Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 InhibitorsSemantic proximity Read

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.Semantic proximity Read

Rate-dependent QT shortening mechanism for the LQT3 deltaKPQ mutant.Semantic proximity Read